Transforming Health
Saving Lives
Pneuma Respiratory
A Revolution on the Path to a Smoke-Free Future.
Pneuma is a MedTech company on a mission to tackle the world’s largest preventable health crisis: smoking. Our groundbreaking water-based aerosol technology is designed to revolutionize how drugs are delivered, beginning with the elimination of harmful toxins and carcinogens caused by heat and combustion in inhaled nicotine products. In the therapeutic space, we have developed the technology to deliver small molecules and, with our low-shear technology, large-molecule biologics to treat lung diseases. With droplets as small as 600 nanometers and respirable fractions exceeding 90%, our platform ensures precise, deep-lung delivery for maximum therapeutic impact.
Our journey is divided into three key areas:
Nicotine & Smoking Cessation – Helping people quit cigarettes and reduce the risks associated with nicotine use.
Chronic Obstructive Pulmonary Disease (COPD) – Addressing one of the most common and debilitating conditions caused by long-term smoking.
Non-Small Cell Lung Cancer (NSCLC) – Developing targeted therapies for lung cancer and precancerous conditions, aiming to save lives and improve outcomes.
By focusing first on smoking cessation and nicotine harm reduction, Pneuma is positioned to make a profound global health impact, potentially saving more than a hundred million lives. Our mission is clear: to save lives by transforming inhaled drug delivery with high-precision aerosol generation technology.
Two Platforms, One Breakthrough Technology
Nicotine delivery platforms hallmarks:
Non-Heated Technology – Non-heated delivery eliminates thermal degradation byproducts such as formaldehyde, acetaldehyde, and benzene, providing a cleaner, less harmful nicotine delivery.
Water-Based Solutions – Water-based aerosols offer a major step forward in harm reduction.
Breath-Actuated Delivery – Intuitively designed to "ride on your breath," delivering precise doses effortlessly as you breathe, improving ease of use and user confidence.
Ultra-Fine Droplet Aerosols – Produces droplets as small as 600 nanometers.
Unprecedented Respirable Fraction – Achieves over 90% respirable fraction.
Reduced Secondhand Nicotine – Achieved by delivering ultra-fine droplets of water-based aerosol that evaporate rapidly in the lungs.
Fully Digital Design – Enables precise dose control, customization, and companion app integration, allowing users to tailor their experience and monitor progress over time.
Targeted Harm Reduction – Developed to reduce health risks associated with inhaled nicotine, providing an alternative for smoking cessation and nicotine use.
Pharmaceutical delivery platform hallmarks:
Ultra-Fine Droplet Precision – Precision control over aerosol droplet size, allowing targeted delivery to different regions of the lung.
High Respirable Fraction – Exceeds 90% aerosol delivery to the lungs. This maximizes the amount of drug deposited in the lungs, thereby reducing the systemic dose required to achieve a given therapeutic effect, which can improve the safety profile of many respiratory treatments.
Versatile Drug Compatibility – Adaptable to a wide range of pharmaceutical compounds, including large-molecule biologics that are challenging to deliver through traditional methods.
Breath-Actuated Delivery – Seamlessly delivers medications as patients breathe, improving ease of use, adherence, and comfort.
Fully Digital Design – Enables precise dosing, customization, and remote monitoring through a connected, app-compatible system, enhancing treatment management and patient engagement.
Broad Application Potential – Designed for various therapeutic areas, including lung conditions (asthma, COPD), cancer (non-small cell lung cancer), and systemic diseases requiring inhaled delivery of complex molecules.
Highly Protected Patent Portfolio
Pneuma’s extensive IP estate includes 139 issued and pending patents, protecting our breakthrough technology across multiple therapeutic applications.
Comprehensive Coverage
Our patent portfolio protects key functions and features that enhance safety, health outcomes, formulations, control, and user experience.
Key Patent Highlight
Patent US 11,793,945 introduces our groundbreaking “Push Mode” aerosol generation technology. This patent covers critical aspects of the device, including the vibrating member, membrane, and ejector plate, which work together to deliver precise and efficient aerosolized treatments.